Ryzodeg® (insulin degludec and insulin aspart) (NN5401)

:Type 1 and 2 diabetes
:Filed for registration

A soluble fixed combination of Tresiba®, the new-generation basal insulin analogue with an ultra-long duration of action, and NovoRapid® (insulin aspart, marketed as NovoLog® in the US), a rapid-acting mealtime insulin. Approved in the EU and Japan and under regulatory review in the US and other major markets.

Company announcements
Increased operating profit by 18% in the first quarter of 2013 (01 May 2013)
Novo Nordisk receives Complete Response Letter in the US for Tresiba® and Ryzodeg® (10 Feb 2013)
Novo Nordisk increased operating profit by 32% in 2012 (31 Jan 2013)
Read more company announcements

Press releases
No press releases matching the search criteria
 

Scientific abstracts

No scientific abstracts matching the search criteria


You can search for more clinical trials on http://clinicaltrials.gov
  •